I read with interest Kanakapura Sriranga et al.’s proposal for a Life-Cycle–Based Evaluation (LCBE) framework for digital health technologies. The move from one-time assessment toward stage-specific, continuous evaluation is timely. Importantly, the authors position the current operationalization as a test of the internal coherence and feasibility of the life-cycle approach rather than as a prescriptive assessment tool (Reference Kanakapura Sriranga, Vasey and Campos1). This appropriately bounded scope raises a further question about the relationship between successive stages.
Different life-cycle stages pose different, legitimate requirements. Developers therefore have strong incentives to optimize development and evidence generation for the hurdle immediately ahead. Kanakapura Sriranga et al. themselves note that medical devices may pass regulatory hurdles while still lacking adequate clinical evidence for subsequent evaluation of cost and relative effectiveness (Reference Kanakapura Sriranga, Vasey and Campos1). This illustrates that evidence sufficient for one decision may leave a later question unresolved.
A further possibility is that the way an immediate requirement is addressed—for example, through choices of population, comparator, endpoints, follow-up, or product and workflow design—may itself alter the options available for satisfying later requirements. Such local optimization can be rational and successful, while its downstream implications may not be explicitly considered when the upstream choice is made.
This question complements rather than challenges life-cycle thinking. Otte et al.’s Life Cycle of Health Technologies 2.0 similarly makes nonlinear progression, feedback, stakeholder-specific knowledge requirements, and decision dependencies explicit (Reference Otte, Gutiérrez-Ibarluzea and Dauben2). Together, these approaches highlight that requirements change across the life cycle and that decisions are connected. They also invite a more specific question: not only what evidence is appropriate for each stage, but whether the route chosen to satisfy one requirement changes the feasibility of satisfying those that follow.
I therefore ask whether life-cycle evaluation should assess not only whether an innovation is ready for the next hurdle, but also whether the development or evidence-generation choices made to clear that hurdle alter the feasibility of meeting requirements that follow.
Making such cross-stage dependencies explicit could complement stage-appropriate evaluation and help preserve flexibility as technologies progress through different decision contexts.
Funding statement
This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Competing interests
The author serves as Member Engagement Co-Chair of the ISPOR Medical Devices & Diagnostics Special Interest Group and as Lead of the Health Economic Modelling Working Group of the German Health Economics Association (DGGÖ). No other conflicts of interest are declared.
Artificial intelligence
ChatGPT was used to assist with drafting and language editing of the letter. All factual statements were independently reviewed by the author, who takes full responsibility for the content, accuracy, integrity, and conclusions of the Letter.
